Table 1.
Demographic and Clinical Characteristics of Enrolled Patients With Hypertension Without and With MCI
| Characteristics | All Patients (N=983) | No MCI (n=819) | MCI (n=164) | P Value |
|---|---|---|---|---|
| Age, y | 64.38+8.26 | 64.38±8.26 | 65.52±8.85 | 0.13 |
| Men, No. (%) | 539 (54.8) | 452 (55.2) | 87 (53.0) | 0.34 |
| DM, No. (%) | 168 (17.1) | 138 (16.8) | 30 (18.3) | 0.36 |
| Education, mean±SD, y | 7.6±4.3 | 7.9±4.7 | 7.0±4.1 | 0.11 |
| Hyperlipidemia, No. (%) | 543 (55.2) | 451 (55.1) | 92 (56.1) | 0.44 |
| Current smoker, No. (%) | 162 (16.5) | 129 (15.8) | 33 (20.1) | 0.11 |
| Current drinker, No. (%) | 221 (22.5) | 186 (22.7) | 35 (21.3) | 0.39 |
| Duration of hypertension, mean±SD, mo | 61.7±17.3 | 59.9±16.8 | 63.2±18.4 | 0.27 |
| SBP, mm Hg | 139±18 | 138±16 | 144±21 | 0.12 |
| DBP, mm Hg | 82±13 | 80±12 | 84±14 | 0.21 |
| Pulse pressure, mm Hg | 61±6 | 60±5 | 63±8 | 0.14 |
| Use of antihypertensive drugs, No. (%) | 535 (54.4) | 451 (52.9) | 84 (51.2) | 0.21 |
| Calcium channel blockers, No. (%) | 319 (32.5) | 272 (33.2) | 47 (28.7) | 0.15 |
| ACEI/ARB, No. (%) | 419 (42.6) | 351 (42.9) | 68 (41.5) | 0.41 |
| β‐Blockers, No. (%) | 183 (18.6) | 159 (19.4) | 24 (14.6) | 0.09 |
| Diuretics, No. (%) | 137 (13.9) | 116 (14.2) | 21 (12.8) | 0.38 |
| Use of antithrombotic drugs, No. (%) | 202 (20.5) | 165 (20.2) | 37 (22.6) | 0.27 |
| Use of lipid‐lowering drugs, No. (%) | 332 (33.8) | 281 (34.3) | 51 (31.1) | 0.24 |
| FBG, mg/dL | 115.16±21.78 | 111.45±20.38 | 117.73±22.91 | 0.39 |
| TC, mg/dL | 175.61±27.18 | 171.32±25.61 | 179.24±29.17 | 0.34 |
| LDL, mg/dL | 129.83±31.42 | 126.58±28.17 | 131.18±32.72 | 0.27 |
| Hemoglobin, g/L | 139.27±10.18 | 142.34±11.11 | 136.55±9.87 | 0.35 |
| BMI, kg/m2 | 24.78±5.14 | 23.98±5.52 | 25.29±6.71 | 0.23 |
| IMT, mm | 1.13±0.24 | 1.10±0.19 | 1.15±0.25 | 0.14 |
| BUN, mg/dL | 58.62 ±28.13 | 53.15±25.26 | 62.15±29.54 | 0.21 |
| SLI, No. (%) | 459 (46.7) | 365 (44.6) | 94 (57.3) | 0.002 |
| PVH, median (IQR) | 2 (1–5) | 2 (1–3) | 3 (2–6) | 0.007 |
| DWMH, median (IQR) | 5 (2–10) | 4 (1–8) | 7 (3–11) | 0.003 |
| Brain atrophy, mean±SD | 0.820±0.025 | 0.827±0.027 | 0.814±0.022 | 0.032 |
| Presence of CMBs, No. (%) | 215 (21.9) | 106 (12.9) | 109 (66.5) | <0.001 |
| No. of CMBs, median (IQR) | 0 (0–0) | 0 (0–0) | 9 (0–19) | <0.001 |
| Distribution of CMBs, No. (%) | ||||
| Lobar | 67 (6.8) | 35 (4.3) | 32 (19.5) | <0.001 |
| Deep or infratentorial | 148 (15.1) | 71 (8.7) | 77 (47.0) | |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, serum urea nitrogen; CMBs, cerebral microbleeds; DBP, diastolic blood pressure; DM, diabetes mellitus; DWMH, deep white matter hyperintensities; FBG, fasting blood glucose; IMT, intima‐media thickness; IQR, interquartile range; LDL, low‐density lipoprotein cholesterol; MCI, mild cognitive impairment; PVH, periventricular hyperintensities; SBP, systolic blood pressure; SLI, silent lacunar infarction; TC, total cholesterol.